DSIP: Research Overview

Delta sleep-inducing peptide (DSIP) is a nonapeptide (nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits by Schoenenberger and Monnier at the University of Basel in 1977. Its isolation was prompted by the observation that perfusate from sleeping donor rabbits could induce a sleep-like EEG state in recipient animals, suggesting the existence of an endogenous sleep-promoting factor. DSIP attracted substantial research interest in the 1980s and early 1990s, particularly around its potential role in sleep regulation and its apparent efficacy in attenuating opioid and alcohol withdrawal symptoms in small clinical studies. Modern research activity is sparse, and DSIP lacks FDA approval for any indication. As of 2026, DSIP (also referred to as emideltide) is scheduled for review by the FDA Pharmacy Compounding Advisory Committee.

What is DSIP?

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nine-residue linear peptide with a molecular weight of approximately 848.9 Da. It is found in the hypothalamus, limbic system, pituitary, and peripheral tissues and is thought to function as a neuromodulator. Unusually for a peptide, DSIP appears to cross the blood–brain barrier with relative ease. Its mechanism of action is not fully characterized — no high-affinity dedicated DSIP receptor has been conclusively identified, and the peptide is thought to interact with multiple receptor systems. DSIP is classified as a research chemical with no approved therapeutic indication in any major jurisdiction.

Mechanism of Action

The molecular mechanism by which DSIP promotes sleep has not been fully established, despite decades of investigation. Early work showed that intraventricular infusion of DSIP in rabbits produced an increase in slow-wave (delta) EEG activity. Proposed mechanisms include modulation of opiate receptor signaling (consistent with its effects on withdrawal symptoms), potentiation of GABA-ergic inhibitory tone, and normalization of circadian pacemaker output. DSIP has also been shown to influence GH, LH, and corticotropin release, suggesting hypothalamic neuromodulatory activity. The absence of a defined receptor and consistent receptor-binding data makes mechanistic precision difficult.

What the Research Shows

The seminal isolation paper (Schoenenberger et al., 1977; PMID 6895513 family) established DSIP's existence and basic sleep-modifying properties in rabbits. Acute and delayed sleep effects were reported in early human studies (Graf et al., 1984; PMID 6895513) in subjects with chronic insomnia, with some patients showing improved sleep onset and altered sleep architecture following intravenous DSIP. The most notable clinical finding came from Kovalzon and Strekalova, and separately from Bjerner-type withdrawal studies, where DSIP administration was associated with marked alleviation of somatic symptoms in opiate- and alcohol-dependent patients: one study (PMID 6328354) reported benefit in 48 of 49 evaluable subjects, including rapid onset of action and sustained suppression of withdrawal signs. These results have not been replicated in modern randomized controlled trials.

The peak of DSIP research was approximately 1977–1995. Effects on sleep of chronic insomniacs were published as recently as 1992 (PMID 1299794), but modern indexed citations on DSIP are sparse and primarily consist of reviews rather than new clinical data. No phase 2 or phase 3 randomized controlled trial for DSIP in any indication has been published. The biological activity of DSIP has also been questioned because commercially synthesized DSIP batches can vary significantly in purity and because early rabbit studies have been difficult to replicate across species and laboratories.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Published dose-finding studies are limited; values reported here come from 1980s–1990s human studies and have not been validated in modern clinical trials. The early insomnia and withdrawal studies used intravenous administration of DSIP, with individual doses in published accounts ranging from approximately 25 to 250 nanomoles. Subcutaneous dosing parameters in humans have not been established in peer-reviewed literature. Doses found in informal research-community sources are not derived from validated clinical data.

References

Citations for this guide are listed below. All PubMed links resolve to the NCBI abstract page for the referenced article.